Last checked at 21 Jan 2015 11:20
e-Therapeutics plc
(the "Company")
Director/PDMR Shareholding
Oxford and Newcastle, UK, 21 January 2015 - e-Therapeutics plc (AIM: ETX), the drug discovery and development company, announces that the Company was notified today that Steve Medlicott, Finance Director, purchased 150,000 ordinary shares in the Company ("Ordinary Shares") at 25.25 pence per share on 21 January 2015. Following the purchase, Mr Medlicott's resultant direct beneficial interest is 250,000 Ordinary Shares, representing 0.09% of the total issued share capital of the Company.
- Ends -
Contacts:
e-Therapeutics plc
Steve Medlicott, Finance Director
Tel: +44 (0) 1993 883125
www.etherapeutics.co.uk
N+1 Singer
Aubrey Powell / Jen Boorer
Tel: +44 (0)20 7496 3000
www.n1singer.com
Instinctif Partners
Melanie Toyne-Sewell / Emma Barlow
Tel: +44 (0) 20 7457 2020
Email: e-therapeutics@instinctif.com
About e-Therapeutics plc
e-Therapeutics is an AIM-quoted drug discovery and development company with a proprietary platform in network pharmacology, an innovative new approach to drug discovery based on advances in network science and chemical biology. The Company's discovery and development activity is currently focused in cancer and disorders of the nervous system.
e-Therapeutics is based at sites in Oxford and Newcastle, UK. For more information about the Company, please visit www.etherapeutics.co.uk.